- HTG Molecular Diagnostics Inc Key Opinion Leader (KOL) “The Role of RNA Profiling in Drug Discovery and Analysis” - Corporate Call TranscriptDec 13, 2022
- Q2 2022 HTG Molecular Diagnostics Inc Earnings Call TranscriptAug 11, 2022€13.06 (+0.93%)Earnings
- HTG Molecular Diagnostics Inc Host a Key Opinion Leader (KOL) Webinar TranscriptJul 27, 2022
- Q1 2022 HTG Molecular Diagnostics Inc Earnings Call TranscriptMay 12, 2022€6.54 (-20.84%)Earnings
- Q4 2021 HTG Molecular Diagnostics Inc Earnings Call TranscriptMar 29, 2022€17.16Earnings
- Q3 2021 HTG Molecular Diagnostics Inc Earnings Call TranscriptNov 10, 2021€51.12 (-1.84%)Earnings
- Q2 2021 HTG Molecular Diagnostics Inc Earnings Call TranscriptAug 12, 2021€59.04 (-4.47%)Earnings
- Q1 2021 HTG Molecular Diagnostics Inc Earnings Call TranscriptMay 13, 2021€36.72 (-6.13%)Earnings
- Q4 2020 HTG Molecular Diagnostics Inc Earnings Call TranscriptMar 25, 2021€54.24 (-2.16%)Earnings
- Q3 2020 HTG Molecular Diagnostics Inc Earnings Call TranscriptNov 10, 2020€53.28 (+8.82%)Earnings
- Q2 2020 HTG Molecular Diagnostics Inc Earnings Call TranscriptAug 11, 2020€95.4 (+2.91%)Earnings
- Q1 2020 HTG Molecular Diagnostics Inc Earnings Call TranscriptMay 13, 2020€64.44 (+0.56%)Earnings
- Q4 2019 HTG Molecular Diagnostics Inc Earnings Call TranscriptMar 25, 2020€53.28 (-1.99%)Earnings
- HTG Molecular Diagnostics, Inc. - Special Call TranscriptDec 13, 2019
- Q3 2019 HTG Molecular Diagnostics Inc Earnings Call TranscriptNov 12, 2019€126 (-3.45%)Earnings
- HTG Molecular Diagnostics, Inc. - Special Call TranscriptOct 29, 2019
- Q2 2019 HTG Molecular Diagnostics Inc Earnings Call TranscriptAug 06, 2019€209.88 (+1.99%)Earnings
- Q1 2019 HTG Molecular Diagnostics Inc Earnings Call TranscriptMay 09, 2019€388.89 (-0.78%)Earnings
- Q4 2018 HTG Molecular Diagnostics Inc Earnings Call TranscriptMar 07, 2019€405 (+0.90%)Earnings
HTG Molecular Diagnostics Inc Host a Key Opinion Leader (KOL) Webinar Transcript
Good morning, and welcome to the HTG Molecular KOL webinar. (Operator Instructions) As a reminder, this call is being recorded, and a replay will be made available on the HTG Molecular website following the conclusion of the event.
I'd now like to turn the call over to John Lubniewski, President and Chief Executive Officer of HTG Molecular. Please go ahead, John.
Yes. Thank you, and I'd like to welcome all of our attendees this morning. I think we've got a really interesting program. We're going to talk about what we see as a very disruptive and exciting new way to develop new lead candidates for pharmaceuticals.
And with us today, we've got an outstanding cast of speakers, most notably, Dr. Robert Spitale from UC Irvine as well as some internal speakers from HTG. So without further ado, I'd like to introduce Dr. Steve Barat. Steve runs our pharma programs. He joined us from Johnson and Janssen, where he was the U.S. Head of
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)